Catalyst Database

LiGeR-HN1, LiGeR-HN2 trials. 6/3/24- Presented interim data at ASCO '24. 7/24/24- Initiated Ph3 mono trial (LiGeR-HN2). 9/30/24- FPI in LiGeR-HN1 trial. 2/18/25- FDA BTD. 2/27/25- LiGeR-HN1 & LiGeR-HN2 enrolling. Clinical update for pembrolizumab combo in H1 2025.

Suspected Mover in Q2 '25: EMBRAZE trial. 5/22/24- Initiated Ph2 POC trial. 9/10/24- Completed enrollment. 2/27/25- Topline data in Q2 2025.

12/14/23 First clinical data reported. 3/20/24- Presented preclinical data at ACS '24. 2/26/25- Report initial data in Q2 2025.

9/25/24 Preclinical data at EADV congress. 10/9/24- FDA clearance of IND. 10/24/24- Dosed first patient (healthy participants). 2/27/25- Report SAD/MAD data in June 2025.

FOX trial in boys w/ DMD. Q3 2024- Advancing trial. 3/3/25- Report data in H1 2025.

ICONIC studies. (ICONIC-ADVANCE, ICONIC-ADVANCE 1&2) Collab w/ Janssen. Initiated in Q1'24. 3/8/25- Announced topline results from Ph3 ICONIC-ADVANCE 1&2studies. 3/6/25- Topline data in Q2 2025. Present data at a major medical conference this year.

8/8/23- Announced enrollment of first healthy volunteer in 12/2022 while first subject enrolled in Q2 2023. 2/25/25- Completed enrollment w/ data in H1 2025.

Suspected mover Q2 '25: w/ ATAI Life Sciences. COMP 005 & 006 Ph3 trials: 11/15/23- Initiate trial in UK. 2/27/25- COMP005 topline data in Q2 2025, COMP006 topline data after the 26-week time point in H2 2026.

5/9/2023- FDA cleared NDA. 11/06/23- Initiated trial. 02/26/24- Trial progressing. 5/29/24- Orphan Medicinal Product Desig. from EC. 2/27/25- Initial data in H1 2025.

MAGNIFY Trial. 7/11/23- First patient dosed. 3/20/25- Made the decision in January 2025 to focus on resources on the development of zervimesine in AD and DLB. Concluded the trial and winding the procedures. Provide results in Q2 2025.